AA
UTHR icon

AlphaMark Advisors’s United Therapeutics UTHR Stock Holding History

AlphaMark Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-31,391
Closed -$2.5M – 516
2019
Q3 		$2.5M Sell
31,391
-918
-3% -$73.9K 1.09% 39
2019
Q2 		$2.52M Sell
32,309
-1,361
-4% -$127K 1.11% 38
2019
Q1 		$3.95M Sell
33,670
-1,077
-3% -$125K 1.67% 17
2018
Q4 		$3.78M Sell
34,747
-2,737
-7% -$317K 1.82% 15
2018
Q3 		$4.79M Sell
37,484
-206
-0.5% -$25.5K 1.93% 11
2018
Q2 		$4.26M Buy
37,690
+834
+2% +$91.7K 1.73% 12
2018
Q1 		$4.14M Buy
36,856
+36,806
+73,612% +$4.68M 1.77% 14
2017
Q4 		$7K Hold
50
– – ﹤0.01% 388
2017
Q3 		$6K Hold
50
– – ﹤0.01% 395
2017
Q2 		$6K Hold
50
– – ﹤0.01% 405
2017
Q1 		$7K Hold
50
– – ﹤0.01% 373
2016
Q4 		$7K Buy
+50
New +$6.38K ﹤0.01% 350

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

AlphaMark Advisors's UTHR Position: Q4 2019 in Review

AlphaMark Advisors sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 31,391 shares — an estimated $2.5M sold.

AlphaMark Advisors first reported a position in UTHR in Q4 2016 and held it in 12 quarters. The position peaked at $4.79M in Q3 2018. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

  • AlphaMark Advisors reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
  • AlphaMark Advisors sold 31,391 United Therapeutics shares in Q4 2019, an estimated $2.5M.
  • AlphaMark Advisors first reported a position in United Therapeutics in Q4 2016 and held it in 12 quarters.
  • AlphaMark Advisors's United Therapeutics position peaked at $4.79M in Q3 2018.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on AlphaMark Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.